LBI-HTA - Publications - Search - [Avastin®/Bevacizumab for metastatic colorectal cancer]

Wild, C. (2005): [Avastin®/Bevacizumab for metastatic colorectal cancer]. HTA-Newsletter 40: 2.

[img]
Preview
PDF (HTA-Newsletter 40) - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
124Kb

Official URL: http://hw.oeaw.ac.at/ita/hta-newsletter?frames=yes


Item Type:HTA Newsletter Item
Keywords:Avastin, bevacizumab, monoclonal antibody, metastatic colorectal cancer (CRC), carcinoma of the colon or the rectum, first-line treatment, drug therapy, combination therapy, FOLFOX, irinotecan, risks, costs
Subjects:QW Microbiology. Immunology
WI Digestive system > WI 400-560 Intestines
Related URLs:
References:1. EMEA 2005: Bevacizumab. URL: http://www.emea.eu.int/humandocs/PDFs/
EPAR/avastin/17199204de1.pdf.

2. Arznei-Telegramm 2005: Angiogenesehemmstoff-Bevacizumab (Avastin) bei kolorektalem Karzinom. URL: http://www.arzneitelegramm.de.

3. NHSC/GB 2004: Bevacizumab (Avastin) for first-line treatment of metastatic colorectal cancer – horizon scanning review. URL: http://pcpoh.bham.ac.uk/
publichealth/horizon/PDF_files/2004reports/Bevacizumab.pdf.
Language:German
Number:40
Deposited on:25 Feb 2008 20:28
Last Modified:18 Apr 2008 19:02

Repository Staff Only: item control page